USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators
Summary
The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582645B2 to Emory University, covering novel chemokine CXCR4 receptor modulators and their therapeutic applications. The patent details compounds, pharmaceutical compositions, and methods for managing conditions such as viral infections, abnormal cellular proliferation, retinal degeneration, inflammatory diseases, and cancer. It also outlines potential co-administration with other active ingredients like antiviral agents or chemotherapeutic agents.
This patent grant signifies the protection of intellectual property related to specific pharmaceutical compounds and their uses. While not imposing direct regulatory obligations on other entities, it establishes exclusive rights for the assignee, potentially impacting future research, development, and commercialization efforts in this therapeutic area. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in CXCR4-related research or treatments, should be aware of this granted patent and its scope.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Chemokine CXCR4 receptor modulators and uses related thereto
Grant US12582645B2 Kind: B2 Mar 24, 2026
Assignee
Emory University
Inventors
Dennis C. Liotta, Edgars Jecs, Robert James Wilson, Huy Hoang Nguyen, Michelle Bora Kim, Lawrence Wilson, Eric Miller, Yesim Altas Tahirovic, Valarie Truax
Abstract
The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
CPC Classifications
C07D 401/12 C07D 401/14 C07D 405/14 C07D 413/14 C07D 417/12 C07D 417/14 C07D 471/04 C07D 487/04 C07D 487/08 A61P 35/00 A61K 31/4725 A61K 31/496 A61K 31/4985 A61K 31/4995 A61K 31/5377 A61K 31/541
Filing Date
2024-05-03
Application No.
18655194
Claims
27
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.